Profile: Ovid Therapeutics Inc (OVID.O)
24 May 2019
Ovid Therapeutics Inc. (Ovid), incorporated on April 1, 2014, is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935.
The Company is developing OV101 for the treatment of Angelman syndrome and Fragile X syndrome. OV101 is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. The Company has commenced a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. OV101, has commenced a Phase II trial, which is primarily a safety trial that is designed to provide proof-of-concept on efficacy parameters, in adults with Angelman syndrome.
The Company is developing OV935 in collaboration with Takeda Pharmaceutical Company Limited (Takeda) for the treatment of rare epileptic encephalopathies. OV935 is a potent, highly selective inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H).
The Company competes with SAGE Therapeutics, Inc., Marinus Pharmaceuticals, Inc., Zynerba Pharmaceuticals, Inc., Zogenix, Inc., GW Pharmaceuticals plc, Sage Therapeutics, Inc., Marinus Pharmaceuticals, Inc., Zynerba Pharmaceuticals, Inc., Insys Therapeutics, Inc. and PTC Therapeutics, Inc.
Ovid Therapeutics Inc
1460 Broadway Ste 15044
NEW YORK NY 10036-7329